Category: biotech

.With a sturdy record for recognizing rough diamonds, Bain Capital Everyday Life Sciences (BCLS) has become a powerful force in biotech committing, pulling in even

.Accept to recently’s Chutes &amp Ladders, our roundup of considerable leadership hirings, firings and retirings throughout the sector. Satisfy deliver the compliment– or the bad–

.Bristol Myers Squibb is paying Excellent Medication $110 million ahead of time to create reagents for ex-spouse vivo T-cell treatments. Perfect, which could possibly acquire

.Bristol Myers Squibb is actually axing an additional significant bet coming from the Caforio time, terminating a deal for Agenus’ TIGIT bispecific antibody three years

.Bristol Myers Squibb has actually had a whiplash change of mind on its BCMA bispecific T-cell engager, halting (PDF) additional growth months after filing to

.AvenCell Rehabs has actually secured $112 thousand in series B funds as the Novo Holdings-backed biotech looks for scientific evidence that it can produce CAR-T

.Atea Pharmaceuticals’ antiviral has actually failed one more COVID-19 trial, but the biotech still holds out really hope the candidate possesses a future in liver

.Pinetree Therapies will aid AstraZeneca plant some plants in its pipe with a brand new contract to develop a preclinical EGFR degrader worth $45 million

.AstraZeneca has actually paid off CSPC Pharmaceutical Group $one hundred million for a preclinical heart disease medicine. The package, which deals with a potential opponent

.AstraZeneca has actually shared a very early take a look at the efficiency of its in-house antibody-drug conjugate (ADC) technology, posting stage 1 record on